- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06751030
Fellesskap, hjemmebasert utdanning, screeningtjenestestrategi for å øke tilgangen til kontroll av livmorhalskreft for HIV-positive kvinner i Nigeria
Strategi for fellesskap, hjemmebasert utdanning, screeningtjenester (CHESS) for å øke tilgangen til kontroll av livmorhalskreft for HIV-positive kvinner i Nigeria
The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims:
- Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population.
- Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity.
- Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program's maintenance and sustainability.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Despite the increased risk of cervical cancer (CC) among women living with HIV (WLWH), access to CC screening in Nigeria remains limited. While advances in prevention programs and antiretroviral therapy have reduced other AIDS-associated malignancies, CC risk in WLWH persists. This study aims to leverage Nigeria's existing HIV treatment infrastructure to integrate home-based CC (HCC) screening for WLWH.
The approach involves adapting the MoMent (MOther MENTor) peer-based HIV support program to include HCC screening and evaluating its implementation and sustainability using the Consolidated Framework for Implementation Research (CFIR) and RE-AIM frameworks. The study has three key aims:
- Adapting the MoMent program to promote home-based HPV screening and follow-up treatment through stakeholder deliberation.
- Implementing and assessing the program's reach, effectiveness, adoption, and fidelity with a sample of 1,500 WLWH.
- Conducting a post-implementation evaluation to identify barriers and enablers for program maintenance and scalability.
Stakeholder input, including perspectives from WLWH, peer counselors, clinical managers, and policymakers, will guide the program's design and execution. By integrating stakeholder insights and addressing systemic challenges, the study aims to advance CC control in Nigeria and provide a scalable model for implementing cancer control strategies for people living with HIV in low- and middle-income countries globally.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
-
Abuja, Nigeria
- APIN Health Initiatives
-
Ibadan, Nigeria
- University of Ibadan
-
Lagos, Nigeria
- Nigeria Institute of Medical Research (NIMR
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Aim 1: The stakeholder deliberation conferences will include stakeholders from the following groups:
- State and National Policymakers
- Organizational-clinical managers
- Mentor mothers
- Women living with HIV (WLWH) Since this is a socio-behavioral component, pregnant individuals may partake. All individuals who take part in this portion of the study will be above 18 and capable of providing informed consent.
Aim 2: This study will only include WLWH aged 25-50. Pregnant individuals will not be included due to the potential for treatment of precancerous lesions. All individuals who partake in the study will be older than 18 and capable of providing informed consent.
Beskrivelse
Inclusion Criteria:
- Patients must be able to perform vaginal self-collection as well as give informed consent
Exclusion Criteria:
- Male gender
- Age <25 or >50
- Unknown or negative HIV status
- Pregnancy
- Hysterectomy
- Inability to give informed consent Inability/refusal to perform vaginal self-collection
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Women living with HIV
During the screening process:
WLWH testing positive for HrHPV 16/18/45 via self-collection will be notified by a Mentor Mother, who, along with Nigerian clinical staff, will assist in scheduling VIA. Treatment follows the standard of care protocol. |
The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
Andre navn:
A cervical cancer screening tool. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Program Reach
Tidsramme: Baseline, Month 6, Month 18
|
Reach evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or reoccurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load. |
Baseline, Month 6, Month 18
|
|
Effectiveness of the Program
Tidsramme: Baseline, Month 6, Month 18
|
Effectiveness evaluated through the provision of home test kits to eligible women, returned samples, number of WLWH positive for high-risk HPV (hrHPV) treated, persistence or recurrence of hrHPV or cervical precancerous lesions post-treatment, and correlation of these results with CD4 and HIV viral load. |
Baseline, Month 6, Month 18
|
|
Adoption of the program
Tidsramme: Baseline, Month 6, Month 18
|
Adoption will be measured through the proportions of MMs who complete training and WLWH who return self-collected (SC) samples |
Baseline, Month 6, Month 18
|
|
Fidelity of the program
Tidsramme: Baseline, Month 6, Month 18
|
Will be measured by peer leaders' monitoring of practices, as well as measuring system barriers and added MoMent program costs per completed home screening |
Baseline, Month 6, Month 18
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Lisa Flowers, MD, MPH, Emory University
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Livmorsykdommer
- Kjønnssykdommer, kvinner
- Genitale neoplasmer, kvinnelige
- Livmor livmorhalssykdommer
- Uterine neoplasmer
- Uterine cervikale neoplasmer
Andre studie-ID-numre
- STUDY00004817
- U01CA275113 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Data shared:
De-identified sociodemographic data (e.g., race/ethnicity, age). Health behavior and health care utilization data from medical records. Cervical pathology results, HPV testing data, laboratory tests (e.g., CD4 and viral load), prescribed HIV medications, and adherence data.
Qualitative data from in-depth interviews and focus group discussions, coded and anonymized.
IPD-delingstidsramme
Start Date: After primary analyses have been completed and results are published (expected within 12 months of study completion).
End Date: Indefinitely, contingent on adherence to data-sharing agreements
Tilgangskriterier for IPD-deling
Researchers will submit a Data Analysis Request Form, detailing their proposed analysis, purpose, and data needed.
Data access will be granted following review and approval. Approved users will sign a Data Use and Confidentiality Agreement. Anonymized data will be shared securely via a designated data repository or encrypted file transfer.
Researchers must commit to using the data for specified purposes, implementing secure data storage, and destroying or returning the data after analyses are completed.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .